2021
N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy
Toma W, Caillaud M, Patel NH, Tran TH, Donvito G, Roberts J, Bagdas D, Jackson A, Lichtman A, Gewirtz DA, Makriyannis A, Malamas MS, Damaj MI. N‐acylethanolamine‐hydrolysing acid amidase: A new potential target to treat paclitaxel‐induced neuropathy. European Journal Of Pain 2021, 25: 1367-1380. PMID: 33675555, DOI: 10.1002/ejp.1758.Peer-Reviewed Original ResearchMeSH KeywordsAmidohydrolasesAnimalsEthanolaminesMicePaclitaxelPeripheral Nervous System DiseasesPPAR alphaConceptsPaclitaxel-induced peripheral neuropathyPaclitaxel-induced mechanical hypersensitivityMechanical hypersensitivitySpinal cordSelective NAAA inhibitorsNAAA inhibitorsPEA levelsDevelopment of PIPNMajor dose-limiting side effectDose-limiting side effectAdministration of palmitoylethanolamidePaclitaxel-induced neuropathyPaclitaxel-treated micePaclitaxel-induced cytotoxicityEvidence of toleranceEffective chemotherapeutic agentIntrinsic rewarding effectsLung tumor cellsNew potential targetsEndogenous palmitoylethanolamidePain aversivenessAcute administrationPeripheral neuropathyControl micePEA administration
2020
Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype
Contreras KM, Caillaud M, Neddenriep B, Bagdas D, Roberts JL, Ulker E, White AB, Aboulhosn R, Toma W, Khalefa T, Adel A, Mann JA, Damaj MI. Deficit in voluntary wheel running in chronic inflammatory and neuropathic pain models in mice: Impact of sex and genotype. Behavioural Brain Research 2020, 399: 113009. PMID: 33181181, PMCID: PMC8961431, DOI: 10.1016/j.bbr.2020.113009.Peer-Reviewed Original ResearchConceptsNeuropathic pain modelChronic constriction injuryMechanical withdrawal thresholdPain modelStrains of miceWithdrawal thresholdDBA/2J miceVoluntary wheelChronic neuropathic pain modelPaclitaxel-treated miceVehicle-treated miceUnilateral intraplantar injectionLower mechanical thresholdsChronic pain reportQuality of lifeChemotherapy agent paclitaxelImpact of sexDifferent mouse strainsCCI miceCCI surgeryConstriction injuryIntraplantar injectionSham surgeryMale C57BL/6JNovel analgesics
2019
The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal
Toma W, Kyte SL, Bagdas D, Jackson A, Meade JA, Rahman F, Chen ZJ, Del Fabbro E, Cantwell L, Kulkarni A, Thakur GA, Papke RL, Bigbee JW, Gewirtz DA, Damaj MI. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. Experimental Neurology 2019, 320: 113010. PMID: 31299179, PMCID: PMC6708482, DOI: 10.1016/j.expneurol.2019.113010.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNicotine rewardPaclitaxel treatmentRewarding effectsTreatment of CIPNPaclitaxel-induced mechanical hypersensitivityTumor-bearing NSG micePaclitaxel-induced peripheral neuropathyNon-small cell lung cancer cell linesCell lung cancer cell linesA549 non-small cell lung cancer cell lineMecamylamine-precipitated withdrawalAntitumor activityIntraepidermal nerve fibersLung cancer cell linesLung tumor growthNSCLC cell viabilityTumor-bearing miceIntrinsic rewarding effectsPlace preference testCancer cell linesConditioned place preference testMechanical hypersensitivityAgonist R
2018
Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy
Curry Z, Wilkerson J, Bagdas D, Kyte S, Patel N, Donvito G, Mustafa M, Poklis J, Niphakis M, Hsu K, Cravatt B, Gewirtz D, Damaj M, Lichtman A. Monoacylglycerol lipase inhibitors reverse paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy. Journal Of Pharmacology And Experimental Therapeutics 2018, 366: jpet.117.245704. PMID: 29540562, PMCID: PMC6038031, DOI: 10.1124/jpet.117.245704.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsApoptosisBenzodioxolesBiomarkersCarbamatesCell Line, TumorCell ProliferationChemokine CCL2Disease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHumansHyperalgesiaInflammationMaleMiceMonoacylglycerol LipasesNociceptionP38 Mitogen-Activated Protein KinasesPaclitaxelPhosphoproteinsPiperidinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2SuccinimidesConceptsAntinociceptive effectPaclitaxel-induced mechanical allodyniaPaclitaxel-induced neuropathic painH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsMonoacylglycerol lipaseMonocyte chemoattractant protein-1Chemotherapy-induced neuropathyPaclitaxel-induced allodyniaPain side effectsPrimary hydrolytic enzymesCell lung cancer cellsSpinal dorsal hornDorsal root gangliaChemoattractant protein-1Novel pharmacologic strategiesPaclitaxel-treated animalsNumerous rodent modelsLung cancer cellsPlace preference paradigmMonoacylglycerol lipase inhibitorsIntrinsic rewarding effectsPhospho-p38 MAPKMechanical allodyniaNeuropathic pain
2017
Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN
Kyte S, Toma W, Bagdas D, Meade J, Schurman L, Lichtman A, Chen Z, Del Fabbro E, Fang X, Bigbee J, Damaj M, Gewirtz D. Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. Journal Of Pharmacology And Experimental Therapeutics 2017, 364: jpet.117.243972. PMID: 29042416, PMCID: PMC5738719, DOI: 10.1124/jpet.117.243972.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPaclitaxel-induced mechanical allodyniaMechanical allodyniaPeripheral neuropathyMouse modelTreatment of CIPNLewis lung carcinoma tumor growthIntraepidermal nerve fiber lossPaclitaxel-induced peripheral neuropathyH460 non-small cell lung cancer cellsNon-small cell lung cancer cellsLung tumor cell proliferationNerve fiber dysfunctionNicotinic acetylcholine receptor subtypesCell lung cancer cellsChronic nicotine administrationNerve fiber lossChronic nicotine treatmentMale C57BL/6J miceAcetylcholine receptor subtypesLung cancer cellsProliferation of A549Receptor-mediated pathwayTumor cell proliferationCIPN treatmentEffects of paclitaxel on the development of neuropathy and affective behaviors in the mouse
Toma W, Kyte S, Bagdas D, Alkhlaif Y, Alsharari S, Lichtman A, Chen Z, Del Fabbro E, Bigbee J, Gewirtz D, Damaj M. Effects of paclitaxel on the development of neuropathy and affective behaviors in the mouse. Neuropharmacology 2017, 117: 305-315. PMID: 28237807, PMCID: PMC5489229, DOI: 10.1016/j.neuropharm.2017.02.020.Peer-Reviewed Original ResearchConceptsCancer chemotherapeutic drugsCancer patientsPreclinical modelsSide effectsAffective symptomsMajor dose-limiting side effectDose-limiting side effectChemotherapeutic drugsLight/dark box testNerve fiber dysfunctionPaclitaxel-treated miceProgression-free survivalSucrose preference testDepression-like behaviorOvarian cancer patientsSevere side effectsAnxiety-like behaviorPotential therapeutic interventionsEffect of paclitaxelAnhedonia-like stateDark box testCold allodyniaNeuropathic painNegative affective symptomsNociceptive effects